Mergers & Acquisitions ·
Liminatus Pharma, Inc. entered into an Amended and Restated Merger Agreement with InnocsAI LLC and NamChul Jung to…
LIMNWLiminatus Pharma, Inc.
Liminatus Pharma, Inc. entered into an Amended and Restated Merger Agreement with InnocsAI LLC and NamChul Jung to restructure a previously announced transaction. On July 2, 2026, the company consummated the merger, acquiring InnocsAI by issuing 11,188,729 shares of common stock and 158,881.1271 shares of Series A Non-Voting Convertible Preferred Stock. The Series A Preferred Stock is convertible into 10,000 shares of common stock per share and requires stockholder approval for conversion. Liminatus Pharma, Inc. is a pharmaceutical company focused on drug development and research.